DLPM Stock | News | Quote | Stock Forum | Friday, January 31,

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
$DLPM Development Capital Group, Inc. DLPM Company Overview 

Development Capital Group, Inc. DLPM Current Price and Quotes
Last Price 0.57
Previous Close 0.56 Open 0.67
Daily Range 0.67 - 0.57 52wk Range 0.74 - 0.07
Volume 11,100 Dividend N/A
Average Vol (3m) 23,964 Yield N/A

DLPM Stock Message Board http://investorshangout.com/search?q=DLPM&...mp;yt1=Go!

Last Updated: Friday, January 31, 2014 01:42:48 AM

Development Capital Group, Inc. DLPM
Company Information

5441 NW 15th Street
Suite 1
Margate, FL 33063

Website: http://www.developmentcapital.com
Phone: (289) 208-8052
Email: info@dlpminc.com

Development Capital Group, Inc. DLPM
Development Capital Group, Inc. (OTCBB: DLPM) invests in and develops businesses and technologies with significant potential for growth and customer acquisition. The Company analyses market trends and looks for opportunities to leverage its understanding of technologies to create efficiencies for under-serviced sectors.

Development Capital Group, Inc. DLPM
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Sep 30, 2013 10-Q
CIK 0001517992
Fiscal Year End 3/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 4213 - Trucking, except local
Business Status Development Stage Company a/o Jan 14, 2014
Incorporated In: FL, USA
Year of Inc. 2010
Employees 4 a/o Jan 14, 2014
Company Officers/Contacts

Johnathan Lindsay CEO
Joseph Ricard President
Company Directors

Johnathan Lindsay
Joseph Ricard
Service Providers

Auditor/Accountant
L.L. Bradford & Company, LLC.
8880 W. Sunset Rd.
Third Floor
Las Vegas, NV, 89148
United States

Legal Counsel
Cane Clark LLP
3273 E. Warm Springs Road
Las Vegas, NV, 89120
United States

Investor Relations Firm
Not Available

Development Capital Group, Inc. DLPM
DLPM Security Details

Share Structure

Market Value1 $9,363,960 a/o Jan 30, 2014
Shares Outstanding 16,428,000 a/o Aug 13, 2013
Float Not Available
Authorized Shares 490,000,000 a/o Jun 30, 2011
Par Value  0.001
Shareholders

Shareholders of Record 61 a/o Jul 03, 2013
Short Selling Data

Short Interest  (%)
Significant Failures to Deliver  No
Transfer Agent(s)

Globex Transfer, LLC

Development Capital Group, Inc. DLPM Financials
Period Ending Mar 31, 2013 Mar 31, 2012 Mar 31, 2011
Total Revenue - - 3
Cost of Revenue - - -
Gross Profit - - 3
Operating Expenses

Research and Development - - -
Sales, General and Admin. 27 53 42
Non-Recurring Items - - -
Other - - -
Operating Income (27) (53) (39)
Income From Continuing Operations

Add'l Income/Expense Items - - -
Earnings Before Interest and Tax (27) (53) -
Interest Expense - - -
Earnings Before Tax (27) (53) -
Income Tax - - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (27) (53) -
Non Recurring Events

Discontinued Operations (2) 53 -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (28) 1 (39)
Preferred Stock and Other Adjustments - - -
Net Income Applicable to Common Shareholders (28) 1 (39)

Development Capital Group, Inc. DLPM Recent News

Jan 30, 2014 Development Capital Group Launches Private Beta For RealtyValuator
Jan 23, 2014 Development Capital Group Introduces Executive Team
Jan 21, 2014 Technology Company Development Capital Group, Raises $680,900 in Finance Round


DLPM Development Capital Group, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=DLPM&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/DLPM/quote
Stock Chart http://www.otcmarkets.com/stock/DLPM/chart
Company Info http://www.otcmarkets.com/stock/DLPM/company-info
Recent News http://www.otcmarkets.com/stock/DLPM/news
Financials http://www.otcmarkets.com/stock/DLPM/financials
Filings and Disclosure http://www.otcmarkets.com/stock/DLPM/filings
Short Sales http://www.otcmarkets.com/stock/DLPM/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/DLPM/insider-transactions
Research Reports http://www.otcmarkets.com/stock/DLPM/research
Summary http://finance.yahoo.com/q?s=DLPM
Historical Prices http://finance.yahoo.com/q/hp?s=DLPM+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=DLPM
Basic Chart http://finance.yahoo.com/q/bc?s=DLPM+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=DLPM+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=DLPM+Headlines
Press Releases http://finance.yahoo.com/q/p?s=DLPM+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=DLPM+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=DLPM+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=DLPM+Industry
Major Holders http://finance.yahoo.com/q/mh?s=DLPM+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=DLPM+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=DLPM+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=DLPM
Balance Sheet http://finance.yahoo.com/q/bs?s=DLPM
Cash Flow http://finance.yahoo.com/q/cf?s=DLPM+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/DLPM
Market Watch http://www.marketwatch.com/investing/stock/DLPM
Bloomberg http://www.bloomberg.com/quote/DLPM:US
Morningstar http://quotes.morningstar.com/stock/s?t=DLPM
Bussinessweek http://investing.businessweek.com/research/st...icker=DLPM
Barchart http://www.barchart.com/quotes/stocks/DLPM
OTC Short Report http://otcshortreport.com/index.php?index=DLPM
Investopedia http://www.investopedia.com/markets/stocks/DLPM/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 229

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 0

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading

Top 5 Most Recently Viewed Articles

SoftBank Expands AI Infrastructure with DigitalBridge Deal

Updated Category News Views 109

SoftBank's Strategic Move in AI Infrastructure SoftBank Group Corp. has recently announced its plans to acquire DigitalBridge Group Inc. in a cash deal worth approximately $4 billion. This move is seen as a pivotal step in SoftBank's commitment to scaling its infrastructure capabilities for artificial intelligence globally. Details of the Acquisition Under the terms of...

Continue Reading
Nio's Bold Moves in the EV Space: What Investors Should Know

Updated Category News Views 158

Forget the Noise, Nio's Got a Game Plan Back in my day, when you heard whispers about a new product launch, it was either a cause for celebration or a catastrophe waiting to happen. Nio, the fast-rising EV player from China, is set to drop its ES9 SUV this May, and trust me, eyes are on the road. They’ve laid out the details like a clear roadmap. Mark Your Calendars Qin...

Continue Reading
Graycliff Partners Declares Landmark Structures Sale to Cerberus

Updated Category News Views 166

Graycliff Partners Announces the Sale of Landmark Structures Graycliff Partners LP has revealed its decision to sell Landmark Structures, an esteemed provider of water and industrial storage infrastructure solutions, to Cerberus Capital Management, a robust investment firm with a global reach. Landmark Structures specializes in designing, manufacturing, and installing...

Continue Reading
Wedbush Recognizes Uber Technologies as a Top Investment

Updated Category News Views 229

Wedbush Identifies Uber Technologies as a Prime Investment Opportunity In a recent analysis, Wedbush has included Uber Technologies Inc (NYSE: UBER) in its prestigious 'best ideas list.' This recognition stems from the company's attractive risk/reward dynamics, particularly as its shares are trading at a lower multiple. Valuation Insights Currently, Uber's stock is...

Continue Reading
Ververica Enhances Global Impact Through Innovative Partnerships

Updated Category News Views 161

Ververica's Global Influence in Real-Time Data Streaming Ververica, the pioneers behind Apache Flink®, recently highlighted its expanding global impact during the Flink Forward Jakarta event. This flagship occasion, known for focusing on cutting-edge data streaming technologies, served as an excellent platform for Ververica to demonstrate its dedication to helping...

Continue Reading